1
|
Zhou J, Wu R, Williams C, Emberson J, Reith C, Keech A, Robson J, Wilkinson K, Armitage J, Collins R, Gray A, Simes J, Baigent C, Mihaylova B. Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Need for primary and secondary healthcare increases following cardiovascular disease (CVD) events but there is no data on comparative increases in costs.
Purpose
To estimate annual primary care and hospital inpatient costs associated with key CVD and other adverse events using the UK Biobank (UKB) individual participant data.
Methods
UKB participants with linked primary care data (192,983 participants) or hospital inpatient episodes data (all 501,807 participants) contributed data to this study. The three categories of primary care services (patient consultations, diagnostic and monitoring tests, prescription medications), and hospital episodes were costed (2020 UK£) using the NHS England reference costs. Annual primary care costs and, separately, annual hospital inpatient costs were modelled as functions of participant characteristics at entry (socio-demographic, clinical, prior diseases) and time-updated first occurrences of myocardial infarction, stroke, coronary revascularization, incident cancer, incident diabetes, vascular death and non-vascular death during follow-up (p-value <0.01 in stepwise covariate selection). One-part generalized linear regression model (GLM) with Poisson distribution and identity link function was used for primary care costs, and two-part model was used for inpatient costs (part 1: logistic regression models probability of incurring costs; part 2: GLM with Poisson distribution and identity link function models costs conditional on incurring any). Separate models were fitted among participants with and without previous CVD at entry into UKB.
Results
Most adverse events were associated with excess primary care and hospital inpatient costs. Compared to people without previous CVD, people with previous CVD had on average larger excess primary care and hospital inpatient costs in years with myocardial infarction, stroke and vascular death; but similar excess costs in years with other events. Among both people without and with previous CVD, the excess annual primary care costs were less than 7% of the excess annual hospital inpatient costs for vascular events (Table). However, following diabetes diagnosis the excess annual primary care costs were higher than the excess annual hospital inpatient costs (Table).
Conclusions
These excess primary and hospital care costs associated with CVD events could inform assessments of interventions and policies to reduce CVD risks in UK.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, UK Medical Research Council (MRC), British Heart Foundation
Collapse
Affiliation(s)
- J Zhou
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - R Wu
- Queen Mary University of London, Wolfson Institute of Population Health , London , United Kingdom
| | - C Williams
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Emberson
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - C Reith
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - A Keech
- University of Sydney, NHMRC Clinical Trials Centre , Sydney , Australia
| | - J Robson
- Queen Mary University of London, Wolfson Institute of Population Health , London , United Kingdom
| | - K Wilkinson
- Public Representative , Oxford , United Kingdom
| | - J Armitage
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - R Collins
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - A Gray
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Simes
- University of Sydney, NHMRC Clinical Trials Centre , Sydney , Australia
| | - C Baigent
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - B Mihaylova
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| |
Collapse
|
2
|
Mihaylova B, Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Wilkinson K, Armitage J, Collins R, Gray A, Simes J, Baigent C. Cost-effectiveness of statin therapy in categories of patients in the UK. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Cardiovascular disease (CVD) mortality has declined steadily over the last few decades across Europe and North America.
Purpose
To provide contemporary estimates of long-term effectiveness and cost-effectiveness of statin therapy in different categories of patients in UK.
Methods
The CTT-UKB micro-simulation model, developed using the Cholesterol Treatment Trialists' Collaboration data (CTT: 118,000 participants; 5 years follow-up), and calibrated in the UK Biobank cohort (UKB: 502,000 participants; 9 years follow-up). The model integrates parametric risk equations for incident myocardial infarction, stroke, coronary revascularization, diabetes, cancer and vascular and nonvascular death, and projects annually these endpoints and survival using patient characteristics at entry. UKB data and linked primary and hospital care data informed healthcare costs in the model (2020 UK£); 2021 UK NHS Drug Tariff informed statin costs (atorvastatin 40mg at £1.22 and 80mg at £1.68 per 28 tablets); and Health Survey for England data informed health-related quality of life in the model. Previous CTT meta-analysis, atorvastatin dose-response randomized trials, and further meta-analyses of statin trials and cohort studies informed effects of 40mg/80mg atorvastatin therapy daily on rates of incident myocardial infarction, stroke, coronary revascularization, vascular death, diabetes, myopathy and rhabdomyolysis.
The model was used to project gains in quality-adjusted life years (QALYs) and additional cost per QALY with lifetime use of atorvastatin 40mg or 80mg daily in categories of UKB participants by sex, age at statin initiation (40–49; 50–59 and 60–70 years), and 10-year CVD risk (QRISK3 risk (%): <5; 5–10, 10–15, 15–20, ≥20). Further scenarios explored effects of 5-year delay of statin initiation in people under 45 years of age or stopping statin therapy at 80 years of age.
Results
Across men and women in categories by age and CVD risk, lifetime use of atorvastatin 40mg daily was associated with increases in survival by 0.44–1.69 years (0.28–1.02 QALYs), and atorvastatin 80mg daily with increases in survival of 0.45–1.87 years (0.32–1.13 QALYs; Figure 1) with gains larger among participants at higher CVD risk. Both atorvastatin 40mg and 80mg doses were in the range of cost-effective treatments with incremental cost per QALY gained with atorvastatin 40mg daily versus no statin therapy below £7200/QALY and with atorvastatin 80mg vs 40mg daily below £16000/QALY (Figure 2) across all patient categories studied. Compared to lifetime statin therapy, stopping therapy at 80 years of age substantially reduced benefits and was not cost-effective in any patient category studied. Similarly, compared to immediate initiation, 5-year delay of statin therapy in 40–45 years old patients was not a cost-effective.
Conclusions
In the UK, statin therapy remains highly cost-effective across men and women 40–70 years old, including those at 10-year CVD risk <5%.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, UK Medical Research Council (MRC), British Heart Foundation
Collapse
Affiliation(s)
- B Mihaylova
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - R Wu
- Queen Mary University of London, Wolfson Institute of Population Health , London , United Kingdom
| | - C Williams
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Zhou
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - I Schlackow
- University of Oxford , Oxford , United Kingdom
| | - J Emberson
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - C Reith
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - A Keech
- University of Sydney, NHMRC Clinical Trials Centre , Sydney , Australia
| | - J Robson
- Queen Mary University of London, Wolfson Institute of Population Health , London , United Kingdom
| | - K Wilkinson
- Public Representative , Oxford , United Kingdom
| | - J Armitage
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - R Collins
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - A Gray
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Simes
- University of Sydney, NHMRC Clinical Trials Centre , Sydney , Australia
| | - C Baigent
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| |
Collapse
|
3
|
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Wilkinson K, Armitage J, Collins R, Gray A, Simes J, Baigent C, Mihaylova B. Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Statin therapy reduces rates of heart attacks and strokes and improves survival in people at increased cardiovascular disease (CVD) risk. However, there is some uncertainty when to start and how long to persist with statin therapy so as to optimise benefits.
Purpose
To project the accrual of benefit with statin therapy in population groups by age at therapy initiation using a newly developed micro-simulation model.
Methods
Participants without previous CVD (N=44,412) and with previous CVD (N=13,061) at entry were randomly selected from the UK Biobank cohort, ensuring sufficient representation in respective categories by age, LDL cholesterol, diabetes and 10-year CVD risk categories (QRISK3 score, for those without previous CVD only). The CTT-UKB model, a CVD micro-simulation model [1], was used to predict subsequent survival and quality-adjusted life years (QALYs) of the participants using their characteristics at entry. Treatment with atorvastatin 40mg daily was used as an example to illustrate the effect of the therapy compared to no such therapy. Scenarios include: (1) lifelong preventive therapy, (2) preventive therapy stopped at 80 years of age, and (3) delayed initiation of preventive therapy by 5 years in participants under 45 years of age.
Results
Statin treatment benefits, measured in QALYs gained, accrue over lifetime. The majority of benefits accrue later in life. Men accumulate larger benefits and earlier than women (Figure 1A). The pattern of benefits accrual is similar for participants with and without previous CVD (data not shown). The higher the participants' CVD risk, the larger and earlier the benefits, with younger participants accruing larger benefits (Figure 1B). Compared with lifelong prevention, stopping treatment at 80 years of age leads to large reductions in overall benefits, especially in women and those at lower CVD risk. For example, compared to lifelong therapy, people without previous CVD who initiate therapy in their 50s, would lose 47% of QALYs benefit (if men), 66% (if women), 73% (if with CVD risk <5%), and 35% (if with CVD risk ≥20%), respectively, if they stop treatment when they reach 80 years of age. Five-year delay of statin therapy initiation in people under 45 years of age reduces their benefits by about 4% on average, though the loss is somewhat larger in people at higher CVD risk (Figure 2).
Conclusion
Benefits from lifelong cardiovascular prevention accrue over peoples' lifespan with large share of benefits accruing at older age. Stopping treatment earlier substantially reduces benefits.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): UK NationalInstitute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, UK Medical Research Council (MRC), and British Heart Foundation
Collapse
Affiliation(s)
- R Wu
- Queen Mary University of London, Wolfson Institute of Population Health , London , United Kingdom
| | - C Williams
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Zhou
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - I Schlackow
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Emberson
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - C Reith
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - A Keech
- University of Sydney, NHMRC Clinical Trials Centre , Sydney , Australia
| | - J Robson
- Queen Mary University of London, Wolfson Institute of Population Health , London , United Kingdom
| | - K Wilkinson
- Public Representative , Oxford , United Kingdom
| | - J Armitage
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - R Collins
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - A Gray
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - J Simes
- University of Sydney, NHMRC Clinical Trials Centre , Sydney , Australia
| | - C Baigent
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| | - B Mihaylova
- University of Oxford, Nuffield Department of Population Health , Oxford , United Kingdom
| |
Collapse
|
4
|
Snir A, Wilson MK, Ju AL, Wong S, Khor L, Naoum C, Wong K, Keech A, Celermajer DS, Ng MK. Novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The optimal method for balloon-expandable transcatheter heart valve (THV) deployment remains unknown. Current implantation protocols are volume-dependent and rely on ad-hoc filling of the deployment apparatus without accounting for annular wall tension during prosthesis expansion, predisposing patients to inconsistent clinical outcomes. During THV deployment, the annular wall tension exerted by the expanding prosthesis is determined by prosthesis diameter and balloon pressure (Laplace's Law).
Objective
We proposed and tested a novel method for balloon-expandable THV deployment, aimed at controlling balloon pressure and the resulting annular wall tension to allow optimal prosthesis-annulus apposition while preventing significant tissue injury.
Methods
330 consecutive patients with severe native aortic stenosis who underwent balloon-expandable THV implantation between 2015–2020 were included. 106 patients were considered high-risk for annular rupture. THVs were deployed until reaching a pre-determined balloon pressure; 4–4.5atm in earlier cases to establish experience and safety, later increasing to 5–6.5atm in most cases. Post-dilatation was performed to reduce >mild angiographic regurgitation (PVR). Using a biomechanical model, annular wall stress (tension) was estimated for each case and assessed against recorded rates of post-dilatation, ≥mild paravalvular regurgitation (PVR) on TTE, new PPM or LBBB and annular rupture.
Results
Patients with wall stress >3MPa (n=184) had reduced post-dilatation rate (p<0.001) and final PVR (≥mild, p=0.014). Annular rupture occurred in 2/3 high-risk cases with wall stress >3.5MPa; no rupture occurred in 102 high-risk cases with wall stress ≤3.5MPa. Based on these results, we defined target deployment wall stress levels (3–3.5MPa) and associated deployment pressure per THV size. Patients within this target range (n=136) had 8.1% new PPM, 12.5% new LBBB, 12.7% mild PVR with no cases of ≥moderate PVR. Importantly, there was an inconsistent relationship between deployment balloon volume and resulting annular wall stress.
Conclusion
Pressure-regulated THV deployment is a simple, easily reproducible, safe and effective method, regardless of high-risk anatomical complexities.
Funding Acknowledgement
Type of funding sources: None. Annular wall stress and PVRModel, stress vs volume and new strategy
Collapse
Affiliation(s)
- A Snir
- University of Sydney, Faculty of Medicine and Health, Sydney, Australia
| | - M K Wilson
- Macquarie University Hospital, Sydney, Australia
| | - A L Ju
- University of Sydney, Faculty of Engineering, Sydney, Australia
| | - S Wong
- Macquarie University Hospital, Sydney, Australia
| | - L Khor
- Macquarie University Hospital, Sydney, Australia
| | - C Naoum
- Macquarie University Hospital, Sydney, Australia
| | - K Wong
- Royal Prince Alfred Hospital, Sydney, Australia
| | - A Keech
- Royal Prince Alfred Hospital, Sydney, Australia
| | | | - M K Ng
- Royal Prince Alfred Hospital, Sydney, Australia
| |
Collapse
|
5
|
Wu R, Williams C, Schlackow I, Zhou J, Emberson J, Reith C, Keech A, Robson J, Wilkinson K, Armitage J, Collins R, Gray A, Simes J, Baigent C, Mihaylova B. A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background and purpose
Cardiovascular disease (CVD) risk of individuals depends on their socio-demographic characteristics, clinical risk factors, and treatments, and strongly influences their quality of life and survival. Individual-based long-term disease models, which aim to more accurately calculate the lifetime consequences, can help to target treatments, develop disease management programmes, and assess the value of new therapies. We present a new micro-simulation CVD model.
Methods
This micro-simulation model was developed using individual participant data from the Cholesterol Treatment Trialists' collaboration (CTT: 118,000 participants; 15 trials) and calibrated (with added socioeconomic deprivation, ethnicity, physical activity, mental illness, cancer and incident diabetes) in the UK Biobank cohort (UKB: 502,000 participants). Parametric survival models estimated risks of key endpoints (myocardial infarction (MI), stroke, coronary revascularisation (CRV), diabetes, cancer and vascular (VD) and nonvascular death (NVD) using participants' age, sex, ethnicity, physical activity, socioeconomic deprivation, smoking history, lipids, blood pressure, creatinine, previous cardiovascular diseases, diabetes, mental illness and cancer at entry and non-fatal incidents of the key endpoints during follow-up. The model integrates the risk equations and enables annual projection of endpoints and survival over individuals' lifetimes. The model was used to project remaining life expectancy across UK Biobank participants.
Results
Nonfatal cardiovascular events and age were the major determinants of CVD risk and, together with incident diabetes and cancer, of individuals' survival. The cumulative incidence of the key endpoints predicted by the CTT-UKB model corresponded well to their observed incidence in the UK Biobank cohort, overall (Figure 1) and in categories of participants by age, sex, prior CVD and CVD risk. Predicted remaining life expectancy across UK Biobank participants without history of CVD ranged between 22 and 43 years in men and between 24 and 46 years in women, depending on their age and CVD risk (Figure 2). Among UK Biobank participants with history of CVD, depending on their age, predicted remaining life expectancy ranged from 20 to 32 years in men and from 26 to 38 years in women.
Conclusion
This new lifetime CVD model accurately predicts morbidity and mortality in a large UK population cohort. It will be made available to provide individualised projections of expected lifetime health outcomes and benefits of treatments.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, UK Medical Research Council (MRC), British Heart Foundation Figure 1. Predicted (in black) versus observed (95% CI; in red) incidence of major clinical outcomes in the UK Biobank.Figure 2. Predicted remaining life expectancy of participants in UK Biobank cohort, by age and CVD risk or previous CVD at entry. QRISK, a 10-year CVD risk scoring algorithm for people without previous CVD, recommended for use in the UK National Health Service.
Collapse
Affiliation(s)
- R Wu
- Queen Mary University of London, London, United Kingdom
| | - C Williams
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - I Schlackow
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - J Zhou
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - J Emberson
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - C Reith
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - A Keech
- University of Sydney, Clinical Trials Centre, Sydney, Australia
| | - J Robson
- Queen Mary University of London, London, United Kingdom
| | - K Wilkinson
- Public Representative, Oxford, United Kingdom
| | - J Armitage
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - R Collins
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - A Gray
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - J Simes
- University of Sydney, Clinical Trials Centre, Sydney, Australia
| | - C Baigent
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| | - B Mihaylova
- University of Oxford, Nuffield Department of Population Health, Oxford, United Kingdom
| |
Collapse
|
6
|
Doyle M, Watson D, Nguyen M, Wu J, Elder D, Ng M, Morton R, Keech A, Shah K, Harris J, Woldendorp K, Seco M. M19 Case Volume, Demographics and Surgical Risk Trends of Patients Undergoing Surgical and Transcatheter Aortic Valve Replacement. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.03.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Snir A, Wilson M, Ju A, Wong S, Khor K, Naoum C, Wong K, Keech A, Celermajer D, Ng M. Novel Pressure-Regulated Deployment Strategy for Improving the Safety and Efficacy of Balloon-Expandable Transcatheter Aortic Valves. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Shah K, Woldendorp K, Harris J, Keech A, Morton R, Ng M, Elder D, Seco M, Nguyen M, Turner L, Wu J, Watson D, Doyle M. R29 Hospital Resource Use and Costs of Isolated Aortic Valve Replacement Procedures in Patients with aortic stenosis, by STS risk scores in New South Wales, Australia. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.03.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Shah K, Elder D, Nguyen M, Turner L, Doyle M, Woldendorp K, Seco M, Law C, Wilson M, Keech A, Ng M, Morton R. 628 Transcatheter Aortic Valve Implantation (TAVI) Versus Surgical Aortic Valve Replacement (SAVR) for Aortic Stenosis: A Cost-Comparison Study. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Xu D, Jenkins A, Ryan C, Keech A, Brown A, Boffa J, O'Dea K, Bursell SE, Brazionis L. Health-related behaviours in a remote Indigenous population with Type 2 diabetes: a Central Australian primary care survey in the Telehealth Eye and Associated Medical Services Network [TEAMSnet] project. Diabet Med 2019; 36:1659-1670. [PMID: 31385331 DOI: 10.1111/dme.14099] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/03/2019] [Indexed: 12/01/2022]
Abstract
AIM There is a wealth of data concerning the health behaviours of Indigenous Australians, but the health behaviours of Indigenous Australians with diabetes are not systematically documented. At the clinical level, understanding a person's health behaviours can help identify and address barriers to diabetes care and promote good clinical outcomes. METHODS We used a novel survey tool to systematically collect health behaviour data on Smoking, Nutrition, Alcohol consumption, Physical activity and Emotional well-being (SNAPE) from Indigenous Australians with Type 2 diabetes in a remote primary care setting in Alice Springs. RESULTS At least one of the five surveys in the SNAPE tool was completed by 210 participants: 30% male, mean age 52.6 years (range 22.9 - 87.4). Fifty per cent of men and 23% of women were current smokers (P < 0.001). None of the participants reported an adequate intake of vegetables. Only 9.6% reported an adequate fruit intake. Some 49% of men and 32% of women consumed alcohol in the past year (P = 0.022), and 46% of drinkers were considered high-risk or likely-dependent drinkers. On average, participants walked 10 min or more at a time 6.0 days a week and spent 4.8 h sitting on a weekday. Mean adapted Patient Health Questionnaire 9 score was 4.61, with 34% of participants having mild depressive symptoms and 11% having moderate-severe depressive symptoms. CONCLUSIONS Our SNAPE survey tool results present a high-risk, disadvantaged Indigenous population with Type 2 diabetes. More resources will be needed to sustainably implement interventions with the goal of improving health behaviours and subsequent long-term health.
Collapse
Affiliation(s)
- D Xu
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, NSW
- The University of Melbourne, Melbourne, VIC
| | - A Jenkins
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, NSW
- The University of Melbourne, Melbourne, VIC
| | - C Ryan
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, NSW
| | - A Keech
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, NSW
| | - A Brown
- South Australian Health and Medical Research Institute, Adelaide, SA
| | - J Boffa
- Central Australian Aboriginal Congress, Alice Springs, NT, Australia
| | - K O'Dea
- The University of Melbourne, Melbourne, VIC
| | - S E Bursell
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, NSW
- The University of Melbourne, Melbourne, VIC
- Telehealth Research Institute, University of Hawaii, Hawaii, HI, USA
| | | |
Collapse
|
11
|
Cao J, Waldman B, O’Connell R, Sullivan D, Gebski V, Marschner I, Scott R, Taskinen M, Simes J, McGill N, Jenkins A, Keech A. Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Shah K, Nguyen M, Seco M, Elder D, Turner L, Wu J, Doyle M, Watson D, Woldendorp K, Keech A, Ng M, Morton R. Comparing Hospital Costs Of Trans-Catheter Aortic Valve Replacement and Isolated Surgical Aortic Valve Replacement in Patients with Aortic Stenosis Treated in New South Wales, Australia. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Keech A, Holgate K, Fildes J, Indraratna P, Cummins L, Lewis C, Yu J. High-intensity Interval Training for Patients with Coronary Artery Disease: Finding the Optimal Balance. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Sivashanmugarajah A, Fulcher J, Sullivan D, Jenkins A, Keech A. A Suggested Clinical Approach for the Diagnosis and Management of ‘Statin Intolerance’. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Barraclough J, Joglekar M, Januszewski A, Martínez G, Celermajer D, Keech A, Hardikar A, Patel S. A MicroRNA Signature Modulated by Colchicine in Acute Coronary Syndrome Patients. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Cao J, Lee S, Dunkley S, Adams M, Keech A. The Case for Extended Thromboprophylaxis in Medically Hospitalised Patients – Not Yet Made. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Elder D, Ng M, Morton R, Keech A, Seco M, Shah K, Turner L, Nguyen M, Woldendorp K, Doyle M, Wu J, Watson D. A Comparison of the Number and Demographics of Patients Undergoing Either Isolated Surgical or a Trans-Catheter Aortic Valve Replacement Following the Introduction of a TAVI Program. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Sever PS, Gouni-Berthold I, Keech A, Giugliano R, Pedersen T, Wasserman S, Im K, Sabatine M, O'Donoghue M. 5002Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.5002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- P S Sever
- Imperial College London, National Heart and Lung Institute, London, United Kingdom
| | | | - A Keech
- University of Sydney, Sydney, Australia
| | - R Giugliano
- Brigham and Women's Hospital, Boston, United States of America
| | - T Pedersen
- Ulleval University Hospital, Oslo, Norway
| | - S Wasserman
- Amgen, Thousand Oaks, United States of America
| | - K Im
- Brigham and Women's Hospital, Boston, United States of America
| | - M Sabatine
- Brigham and Women's Hospital, Boston, United States of America
| | - M O'Donoghue
- Brigham and Women's Hospital, Boston, United States of America
| | | |
Collapse
|
19
|
O'Donoghue M, Giugliano R, Keech A, Kanevsky E, Im K, Pineda A, Somaratne R, Sever P, Pederson T, Sabatine M. Lipoprotein(a), PCSK9 Inhibition and cardiovascular risk: Insights from the Fourier trial. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.912] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
20
|
Hakansson S, Jones M, Ristov M, Marcos L, Clark T, Ram A, Morey R, Franklin A, McCarthy C, Carli L, Ward R, Keech A. Intensity-dependent effects of aerobic training on pressure pain threshold in overweight men: A randomized trial. Eur J Pain 2018; 22:1813-1823. [DOI: 10.1002/ejp.1277] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/25/2018] [Indexed: 12/12/2022]
Affiliation(s)
- S. Hakansson
- School of Medical Sciences; University of New South Wales; Sydney Australia
- Department of Biomedicine; Karolinska Institutet; Stockholm Sweden
| | - M.D. Jones
- School of Medical Sciences; University of New South Wales; Sydney Australia
- Kirby Institute; University of New South Wales; Sydney Australia
- Neuroscience Research Australia; Sydney Australia
| | - M. Ristov
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - L. Marcos
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - T. Clark
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - A. Ram
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - R. Morey
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - A. Franklin
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - C. McCarthy
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - L.D. Carli
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - R. Ward
- School of Medical Sciences; University of New South Wales; Sydney Australia
| | - A. Keech
- School of Medical Sciences; University of New South Wales; Sydney Australia
| |
Collapse
|
21
|
Brazionis L, Jenkins A, Keech A, Ryan C, Brown A, Boffa J, Bursell S. Diabetic retinopathy in a remote Indigenous primary healthcare population: a Central Australian diabetic retinopathy screening study in the Telehealth Eye and Associated Medical Services Network project. Diabet Med 2018; 35:630-639. [PMID: 29405370 DOI: 10.1111/dme.13596] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/30/2018] [Indexed: 01/29/2023]
Abstract
AIM To determine diabetic retinopathy prevalence and severity among remote Indigenous Australians. METHODS A cross-sectional diabetic retinopathy screening study of Indigenous adults with Type 2 diabetes was conducted by locally trained non-ophthalmic retinal imagers in a remote Aboriginal community-controlled primary healthcare clinic in Central Australia and certified non-ophthalmic graders in a retinal grading centre in Melbourne, Australia. The main outcome measure was prevalence of any diabetic retinopathy and sight-threatening diabetic retinopathy. RESULTS Among 301 participants (33% male), gradable image rates were 78.7% (n = 237) for diabetic retinopathy and 83.1% (n = 250) for diabetic macular oedema, and 77.7% (n = 234) were gradable for both diabetic retinopathy and diabetic macular oedema. For the gradable subset, the median (range) age was 48 (19-86) years and known diabetes duration 9.0 (0-24) years. The prevalence of diabetic retinopathy was 47% (n = 110) and for diabetic macular oedema it was 14.4% (n = 36). In the fully gradable imaging studies, sight-threatening diabetic retinopathy prevalence was 16.2% (n = 38): 14.1% (n = 33) for clinically significant macular oedema, 1.3% (n = 3) for proliferative diabetic retinopathy and 0.9% (n = 2) for both. Sight-threatening diabetic retinopathy had been treated in 78% of detected cases. CONCLUSIONS A novel telemedicine diabetic retinopathy screening service detected a higher prevalence of 'any' diabetic retinopathy and sight-threatening diabetic retinopathy in a remote primary care setting than reported in earlier surveys among Indigenous and non-Indigenous populations. Whether the observed high prevalence of diabetic retinopathy was attributable to greater detection, increasing diabetic retinopathy prevalence, local factors, or a combination of these requires further investigation and, potentially, specific primary care guidelines for diabetic retinopathy management in remote Australia. Clinical Trials registration number: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN 12616000370404.
Collapse
Affiliation(s)
- L Brazionis
- Department of Medicine, University of Melbourne, Melbourne, Australia
| | - A Jenkins
- Department of Medicine, University of Melbourne, Melbourne, Australia
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, Australia
| | - A Keech
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, Australia
| | - C Ryan
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, Australia
| | - A Brown
- SAHMRI, University of South Australia, Adelaide, Australia
| | - J Boffa
- Central Australian Aboriginal Congress, Alice Springs, Australia
| | - S Bursell
- National Health and Medical Research Council of Australia Clinical Trials Centre, University of Sydney, Sydney, Australia
- Telehealth Research Unit, University of Hawaii, HI, USA
| |
Collapse
|
22
|
Abstract
Purpose To evaluate tear osmolarity after using a hydroxypropyl-guar (HP-guar)-based lubricating eye drop four times daily (QID) for 3 weeks. Methods Thirty-one participants with dry eye disease (Ocular Surface Disease Index [OSDI] score ≥20 and tear osmolarity ≥300 mOsm/L in at least one eye) were enrolled in this prospective, dispensing, non-randomized study involving a baseline visit and 3-week follow-up. Tear osmolarity, non-invasive tear break up time (NITBUT), conjunctival hyperemia, corneal and conjunctival staining were determined at baseline. Participants were instructed to instill one drop of a HP-guar-based drop QID in each eye for 3 weeks. At the follow-up visit, the symptoms and ocular surface parameters were reassessed. At this visit, one HP-guar drop was instilled into each eye and osmolarity was measured after 15 minutes, to examine short-term changes in osmolarity. Results Twenty-eight participants completed the study (5M, 23F; median age 54 yrs, range 25-83 yrs). At baseline, mean OSDI score was 44.9±15.2 and mean osmolarities were 314.63±11.9/306.6±10.1 mOsm/L (worst eye [WE]/better eye [BE]). After 3 weeks, mean osmolarity reduced to 307.7±15.7/303.9±11.3 mOsm/L (WE/BE; p<0.05 and p=0.228, respectively) and mean OSDI scores reduced to 28.3±17.0 (p<0.01). A significant reduction in osmolarity was observed 15 minutes after instilling the lubricating drop (p<0.05 WE, p=0.09 BE). Significant improvements in central corneal staining (p<0.05 OU) and NITBUT (p<0.05 WE only) were observed. Reductions in conjunctival staining and hyperemia were observed, but were not significant (p>0.05). Conclusions A significant reduction in tear osmolarity and improvements in dry eye symptoms, corneal staining, and NITBUT were observed after 3 weeks of QID use of a HP-guar-based lubricant drop. A decrease in osmolarity was also demonstrated 15 minutes after drop instillation.
Collapse
Affiliation(s)
- Alison Ng
- Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, ON, Canada
| | - Adam Keech
- Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, ON, Canada
| | - Lyndon Jones
- Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, ON, Canada
| |
Collapse
|
23
|
Khandkar C, Vaidya K, Penglase R, Cai K, Shin J, Hunyor I, Keech A, McGill N. A Rare Case of Infiltrative Cardiomyopathy Secondary to Scleromyxoedema. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Wewege MA, Ward RE, Keech A. Reply to letter to the editor: high-intensity interval training vs. moderate-intensity continuous training: the lack of equalization, an ongoing problem. Obes Rev 2017; 18:1225-1226. [PMID: 28730659 DOI: 10.1111/obr.12586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 06/08/2017] [Indexed: 12/01/2022]
Affiliation(s)
- M A Wewege
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - R E Ward
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - A Keech
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| |
Collapse
|
25
|
Wewege M, van den Berg R, Ward RE, Keech A. The effects of high-intensity interval training vs. moderate-intensity continuous training on body composition in overweight and obese adults: a systematic review and meta-analysis. Obes Rev 2017; 18:635-646. [PMID: 28401638 DOI: 10.1111/obr.12532] [Citation(s) in RCA: 288] [Impact Index Per Article: 41.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2017] [Revised: 02/12/2017] [Accepted: 02/12/2017] [Indexed: 12/17/2022]
Abstract
OBJECTIVE The objective of this study is to compare the effects of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) for improvements in body composition in overweight and obese adults. METHODS Trials comparing HIIT and MICT in overweight or obese participants aged 18-45 years were included. Direct measures (e.g. whole-body fat mass) and indirect measures (e.g. waist circumference) were examined. RESULTS From 1,334 articles initially screened, 13 were included. Studies averaged 10 weeks × 3 sessions per week training. Both HIIT and MICT elicited significant (p < 0.05) reductions in whole-body fat mass and waist circumference. There were no significant differences between HIIT and MICT for any body composition measure, but HIIT required ~40% less training time commitment. Running training displayed large effects on whole-body fat mass for both HIIT and MICT (standardized mean difference -0.82 and -0.85, respectively), but cycling training did not induce fat loss. CONCLUSIONS Short-term moderate-intensity to high-intensity exercise training can induce modest body composition improvements in overweight and obese individuals without accompanying body-weight changes. HIIT and MICT show similar effectiveness across all body composition measures suggesting that HIIT may be a time-efficient component of weight management programs.
Collapse
Affiliation(s)
- M Wewege
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - R van den Berg
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - R E Ward
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - A Keech
- Department of Exercise Physiology, School of Medical Sciences, University of New South Wales, Sydney, Australia
| |
Collapse
|
26
|
Ngo W, Srinivasan S, Keech A, Keir N, Jones L. Self versus examiner administration of the Ocular Surface Disease Index ©. J Optom 2017; 10:34-42. [PMID: 27233156 PMCID: PMC5219841 DOI: 10.1016/j.optom.2016.04.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 04/06/2016] [Accepted: 04/23/2016] [Indexed: 06/05/2023]
Abstract
PURPOSE To compare the difference in Ocular Surface Disease Index© (OSDI) scores when participants were given the OSDI to complete on their own (self-guided, SG), versus under the guidance of the examiner (examiner-guided, EG). METHODS 100 participants enrolled in this prospective two-visit study (fifty under-45 years old, 38F/12M; and fifty 45 years-and-older, 42F/8M). Participants who scored ≥1 on the Subjective Evaluation of Symptoms of Dryness (SESoD) were included in this study. Participants completed the OSDI SG during the first visit. Participants returned the next day and repeated the OSDI, but with EG (with standardized instructions). Participants were under deception and believed that they were comparing the OSDI to the SESoD. RESULTS The mean OSDI score of the SG and EG administration was 32.0±17.3 and 33.8±19.6 respectively (p>0.05) with 95% limits of agreement between -20.6 and +24.2. The correlation between SG and EG administration was Spearman's r=0.81, p<0.01. The mean difference between SG and EG was not significant (p>0.05) for both the under-45 group, and 45-and-older group. The 95% limits of agreement for the under-45 group were smaller than the 45-and-older group (under-45: [-15.5, +13.1,], 45-and-older: [-23.3, +32.2]). A significant difference was found between 8 of the 12 questions items (all p≤0.01). However, the mean difference for each was <0.6 and was not considered to be clinically significant. CONCLUSION There was no clinically significant difference in OSDI score between SG and EG administration, however having instructions provided with EG administration affected variability of scores in the older group more than the younger group.
Collapse
Affiliation(s)
- William Ngo
- Centre for Contact Lens Research, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1.
| | - Sruthi Srinivasan
- Centre for Contact Lens Research, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1
| | - Adam Keech
- Centre for Contact Lens Research, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1
| | - Nancy Keir
- Centre for Contact Lens Research, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1
| | - Lyndon Jones
- Centre for Contact Lens Research, School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1
| |
Collapse
|
27
|
Tan A, Greenberg B, Keech A, Plumb P, Hughes S, Harder L. A-59Neuropsychological Functioning in Pediatric Demyelinating Diseases: A Comparison Between Multiple Sclerosis (MS) and Acute Disseminated Encephalomyelitis (ADEM). Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.59] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Tan A, Greenberg B, Keech A, Plumb P, Hughes S, Harder L. A-57Assessing Executive Functioning Deficits in Pediatric Multiple Sclerosis: Association Between Objective Measures and Subjective Rating Scales. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
King E, Yuan J, Kong S, Dunn L, Stocker R, Keech A, Jenkins A, Ng M. Hypoxia Tolerance in Diabetes Mellitus: The Role of Fenofibrate in Facilitating Protective Metabolic Reprogramming. Heart Lung Circ 2016. [DOI: 10.1016/j.hlc.2016.06.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Chia N, Fulcher J, Keech A. Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure. Intern Med J 2016; 46:653-62. [PMID: 26109136 DOI: 10.1111/imj.12839] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Heart failure causes significant morbidity and mortality, with recognised underutilisation rates of guideline-based therapies. Our aim was to review current evidence for heart failure treatments and derive a mnemonic summarising best practice, which might assist physicians in patient care. Treatments were identified for review from multinational society guidelines and recent randomised trials, with a primary aim of examining their effects in systolic heart failure patients on mortality, hospitalisation rates and symptoms. Secondary aims were to consider other clinical benefits. MEDLINE and EMBASE were searched using a structured keyword strategy and the retrieved articles were evaluated methodically to produce an optimised reference list for each treatment. We devised the mnemonic BANDAID (2) , standing for beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine (or potentially neprilysin inhibitor), diuretics, aldosterone antagonist, ivabradine, devices (automatic implantable cardioverter defibrillator, cardiac resynchronisation therapy or both) and digoxin as a representation of treatments with strong evidence for their use in systolic heart failure. Treatment with omega-3 fatty acids, statins or anti-thrombotic therapies has limited benefits in a general heart failure population. Adoption of this mnemonic for current evidence-based treatments for heart failure may help improve prescribing rates and patient outcomes in this debilitating, high mortality condition.
Collapse
Affiliation(s)
- N Chia
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - J Fulcher
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - A Keech
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
31
|
Reith C, Blackwell L, Emberson J, Mihaylova B, Armitage J, Fulcher J, Keech A, Simes J, Baigent C, Collins R. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J 2016; 176:63-9. [PMID: 27264221 PMCID: PMC4906243 DOI: 10.1016/j.ahj.2016.01.016] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 01/16/2016] [Indexed: 01/14/2023]
Abstract
The Cholesterol Treatment Trialists' (CTT) Collaboration was originally established to conduct individual participant data meta-analyses of major vascular events, cause-specific mortality, and site-specific cancers in large, long-term, randomized trials of statin therapy (and other cholesterol-modifying treatments). The results of the trials of statin therapy and their associated meta-analyses have shown that statins significantly reduce the risk of major vascular events without any increase in the risk of nonvascular causes of death or of site-specific cancer, but do produce small increases in the incidence of myopathy, diabetes, and, probably, hemorrhagic stroke. The CTT Collaboration has not previously sought data on other outcomes, and so a comprehensive meta-analysis of all adverse events recorded in each of the eligible trials has not been conducted. This protocol prospectively describes plans to extend the CTT meta-analysis data set so as to provide a more complete understanding of the nature and magnitude of any other effects of statin therapy.
Collapse
|
32
|
Sullivan DR, Watts GF, Nicholls SJ, Barter P, Grenfell R, Chow CK, Tonkin A, Keech A. Clinical guidelines on hyperlipidaemia: recent developments, future challenges and the need for an Australian review. Heart Lung Circ 2015; 24:495-502. [PMID: 25676115 DOI: 10.1016/j.hlc.2014.12.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 12/03/2014] [Accepted: 12/08/2014] [Indexed: 12/11/2022]
Abstract
Large reductions in cardiovascular disease (CVD) mortality have been achieved over the last 50 years in developed countries. The health policies that have contributed so much to this success have largely been coordinated by means of expert guidelines for the management of the classic modifiable risk factors such as blood pressure, diabetes and blood lipids. National and international guidelines for lipid management have demonstrated a high degree of consistency between numerous sets of recommendations. It has been argued that some important components of the consensus that has been established over the past decade have been challenged by the latest guidelines of the American Heart Association - American College of Cardiologists (AHA-ACC). Clinicians can be reassured that continued reliance on extensive scientific evidence has reaffirmed the importance of lipid metabolism as a modifiable risk factor for atherosclerotic cardiovascular disease. On the other hand, the recent AHA-ACC guidelines suggest changes in the strategies by which metabolic risk factors may be modified. This small number of important changes should not be sensationalised because these differences usefully reflect the need for guidelines to evolve to accommodate different contexts and changing perspectives as well as emerging issues and new information for which clinical trial evidence is incomplete. This article will consider the recent policies and responses of national and supranational organisations on topics including components of CVD risk assessment, sources of CVD risk information and re-appraisal of lipid-lowering interventions. Timely review of Australian lipid management guidelines will require consideration of these issues because they are creating a new context within which new guidelines must evolve.
Collapse
Affiliation(s)
- D R Sullivan
- Department of Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, NSW.
| | - G F Watts
- Department of Medicine, University of Western Australia, Perth, WA
| | - S J Nicholls
- South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA
| | - P Barter
- Centre for Vascular Research, University of NSW, Sydney NSW
| | - R Grenfell
- National Heart Foundation Director of Cardiovascular Health, Melbourne Vic
| | - C K Chow
- The George Institute for International Health, University of Sydney, Camperdown, Sydney NSW
| | - A Tonkin
- Cardiovascular Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic
| | - A Keech
- NHMRC Clinical Trials Centre, University of Sydney and Royal Prince Alfred Hospital, University of Sydney, NSW
| |
Collapse
|
33
|
King E, Chen S, Yuan J, Jenkins A, Keech A, Ng M. The role of fenofibrate in metabolic reprogramming in hyperglycaemia and hypoxia. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
van der Linde D, Davies L, Sherrah A, Bannon P, Vallely M, Wilson M, Turner L, Keech A, Jeremy R. Comparative outcomes after acute aortic dissection in genetic aortopathy syndromes. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Chen S, King E, Yuan J, Jenkins A, Keech A, Ng M. Effects of fenofibrate on hypoxia tolerance in diabetes and associated molecular mechanisms. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
36
|
Yuan J, Rajamani K, King E, Bursill C, Lecce L, Jenkins A, Keech A, Ng M. Fenofibrate rescues diabetes-related impairment of ischaemia-mediated angiogenesis by a PPARα independent pathway. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Fabritz L, Fortmuller L, Vloumidi E, Yue TY, Syeda F, Kirchhof P, Leube R, Krusche C, Chin SH, Winter J, Brack KE, Ng GA, Ng FS, Holzem KM, Koppel AC, Janks D, Wit AL, Peters NS, Efimov IR, Chowdhury RA, El-Harasis MA, Dupont E, Terracciano CMN, Peters NS, Mellor GJ, Raju H, de Noronha SV, Papadakis M, Sharma S, Behr ER, Sheppard MN, Jamil-Copley S, Bai W, Ariff B, Lim PB, Koa-Wing M, Kyriacou A, Hayat S, Sohaib A, Qureshi N, Sandler B, O'Regan D, Whinnett Z, Davies W, Rueckert D, Kanagaratnam P, Peters N, Lambiase PD, Chow AW, Lowe MD, Segal OR, Ahsan S, de Bono J, Dhaliwal M, Mfuko C, Ng A, Sandilands A, Paisey J, Roberts P, Morgan JM, McCready J, Yue A, Ullah W, Hunter R, Lovell M, Dhinoja M, Sporton S, Earley M, Schilling R, Ghosh J, Martin A, Keech A, Chan KH, Gomes S, Singarayar S, McGuire M, Lee G, Hunter R, Berriman T, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Unsworth B, Mayet J, Abrams D, Dhinoja M, Sporton S, Earley M, Schilling RJ, Bowers RW, Mulholland V, Balasubramaniam RN, Paisey JR, Sopher SM, Chu GS, Chin SH, Winter J, Armstrong S, Masca N, Almeida TP, Brown PD, Sandilands AJ, Schlindwein FS, Ng GA. ABSTRACTS FOR ORAL PRESENTATION, SESSION 2, HRC 2013. Europace 2013. [DOI: 10.1093/europace/eut315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Abstract
AIM To generate data on the variability of tear osmolarity in a control (normal, non-dry eye) and symptomatic dry eye population (Ocular Surface Disease Index: OSDI ≥20). A secondary outcome is the determination of the effect that tear collection technique has on the osmolarity of the sample. MATERIALS AND METHODS This was a two-phase study that recruited 20 subjects (n = 10 normal, n = 10 dry eye) to evaluate the influence of time between measurements (Phase I) and 30 subjects (n = 15 normal, n = 15 dry eye) to evaluate the influence of collection technique (Phase II). As part of Phase I, serial tear osmolarity measurements were performed on each eye; four separated by 15 min followed by four separated by 1 min, at each of three visits. Phase II compared the consecutive measurement of four in vivo tear samples to four in vitro measurements on tears collected and dispensed from a glass capillary tube. RESULTS During Phase I, the dry eye group had a significantly higher maximum osmolarity (334.2 ± 25.6 mOsm/L) compared to the normal group (304.0 ± 8.4 mOsm/L, p = 0.002). No significant differences were observed whether collections were performed at 15 or 1 min intervals. During Phase II, the in vivo osmolarity was equivalent to in vitro measurements from glass capillary tube samples for both the dry eye group (323.0 ± 16.7 mOsm/L versus 317.7 ± 24.8, p = 0.496), and for the normal subjects (301.2 ± 7.2 mOsm/L versus 301.9 ± 16.0 mOsm/L, p = 0.884). CONCLUSION Symptomatic dry eye subjects exhibited a significantly higher tear osmolarity and variation over time than observed in normal subjects, reflecting the inherent tear film instability of dry eye disease. There was no change in the distribution of tear osmolarity measurements whether tears were collected in rapid succession or given time to equilibrate, and collection method had no impact on tear osmolarity.
Collapse
Affiliation(s)
- Adam Keech
- Centre for Contact Lens Research, School of Optometry, University of Waterloo, Waterloo, ON, Canada.
| | | | | |
Collapse
|
39
|
Colquhoun D, Bensoussan A, Braun L, Hill K, Keech A, Kostner K, Rosenfeldt F, Walker R, Watts G. Complementary Medicines in Cardiovascular Disease – Review of the Evidence by the National Institute of Complementary Medicine 2013. Heart Lung Circ 2013. [DOI: 10.1016/j.hlc.2013.05.621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Yong A, Ho M, Shah M, Chawantanpipat C, O’Connell R, Keech A, Kritharides L, Fearon W, Ng M. The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Harmer J, Veillard A, Skilton M, Keech A, Celermajer D. Fenofibrate and Carotid Intima-Media Thickness in Adults with Type 2 Diabetes Mellitus: A FIELD Sub-Study. Heart Lung Circ 2011. [DOI: 10.1016/j.hlc.2011.05.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TME, Pardy C, Colman P, Keech A. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54:32-43. [PMID: 20668832 DOI: 10.1007/s00125-010-1854-1] [Citation(s) in RCA: 149] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2010] [Accepted: 06/18/2010] [Indexed: 12/24/2022]
Abstract
AIMS/HYPOTHESIS We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. METHODS Baseline and year 2 renal status were examined in relation to clinical and biochemical characteristics. Outcomes included total cardiovascular disease (CVD), cardiac and non-cardiac death over 5 years. RESULTS Lower estimated GFR (eGFR) vs eGFR ≥90 ml min⁻¹ 1.73 m⁻² was a risk factor for total CVD events: (HR [95% CI] 1.14 [1.01-1.29] for eGFR 60-89 ml min⁻¹ 1.73 m⁻²; 1.59 [1.28-1.98] for eGFR 30-59 ml min⁻¹ 1.73 m⁻²; p < 0.001; adjusted for other characteristics). Albuminuria increased CVD risk, with microalbuminuria and macroalbuminuria increasing total CVD (HR 1.25 [1.01-1.54] and 1.19 [0.76-1.85], respectively; p = 0.001 for trend) when eGFR ≥90 ml min⁻¹ 1.73 m⁻². CVD risk was further modified by renal status changes over the first 2 years. In multivariable analysis, 77% of the effect of eGFR and 81% of the effect of albumin:creatinine ratio were accounted for by other variables, principally low HDL-cholesterol and elevated blood pressure. CONCLUSIONS/INTERPRETATION Reduced eGFR and albuminuria are independent risk factors for cardiovascular events and mortality rates in a low-risk population of mainly European ancestry. While their independent contributions to CVD risk appear small when other risk factors are considered, they remain excellent surrogate markers in clinical practice because they capture risk related to a number of other characteristics. Therefore, both should be considered when assessing prognosis and treatment strategies in patients with diabetes, and both should be included in risk models.
Collapse
Affiliation(s)
- P L Drury
- Auckland Diabetes Centre, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Rajamani K, Donoghoe M, Li L, Ting RD, Colman P, Scott R, Laakso M, Keech A. MS546 FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)71046-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Foucher C, Le Malicot K, Ansquer JC, Gebski V, Keech A. MS520 FENOFIBRATE TREATMENT REDUCES THE OCCURRENCE OF RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)71020-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
45
|
Harmer J, Keech A, Veillard A, Skilton M, Griffiths K, Marwick T, Watts G, Meredith I, Celermajer D. Fenofibrate and Short-Term Improvement in Endothelial Function in Adults with Type 2 Diabetes Mellitus: A FIELD Substudy. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Kiat A, Dignan R, Gebski V, Keech A. A Novel Technique of Continuous Parasternal Ropivacaine Infusion after Cardiac Surgery: Background Study to the PAINLESS Trial. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
47
|
Dignan R, Keech A, Powell C, Turner L, Mann K, Hughes C, Gebski V. Is Home Warfarin Self-Management Effective? Results of the Warfarin S.M.A.R.T. Study and Uptake of Self-Management. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
48
|
Harmer J, Keech A, Veillard A, Skilton M, Griffiiths K, Marwick T, Watts G, Meredith I, Celermajer D. Cigarette Smoking and Albuminuria are Associated with Impaired Arterial Smooth Muscle Function in Patients with Type 2 Diabetes Mellitus: A FIELD Sub-Study. Heart Lung Circ 2010. [DOI: 10.1016/j.hlc.2010.06.719] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Glasier MA, Keech A, Sheardown H, Subbaraman LN, Jones L. Conformational and Quantitative Characterization of Lysozyme Extracted from Galyfilcon and Senofilcon Silicone Hydrogel Contact Lenses. Curr Eye Res 2009; 33:1-11. [DOI: 10.1080/02713680701830278] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
50
|
Keech A. Abstract: 1446 USE OF PPAR AGONISTS IN THE MANAGEMENT AND PREVENTION OF VASCULAR DISEASE IN DIABETES. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71597-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|